If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
=== Other environmental factors === Allergic diseases are more common in industrialized countries than in countries that are more traditional or agricultural, and there is a higher rate of allergic disease in urban populations versus rural populations, although these differences are becoming less defined. Historically, the trees planted in urban areas were predominantly male to prevent litter from seeds and fruits, but the high ratio of male trees causes high pollen counts, a phenomenon that horticulturist Tom Ogren has called "botanical sexism". Alterations in exposure to microorganisms is another plausible explanation, at present, for the increase in atopic allergy. Endotoxin exposure reduces release of inflammatory cytokines such as TNF-α, IFNγ, interleukin-10, and interleukin-12 from white blood cells (leukocytes) that circulate in the blood. Certain microbe-sensing proteins, known as Toll-like receptors, found on the surface of cells in the body, are also thought to be involved in these processes.
=== Carbon === 11C decays by positron emission with a half-life of ca. 20 min. 11C is one of the isotopes often used in positron emission tomography. 14C decays by beta decay, with a half-life of 5730 years. It is continuously produced in the upper atmosphere of the earth, so it occurs at a trace level in the environment. However, it is not practical to use naturally occurring 14C for tracer studies. Instead it is made by neutron irradiation of the isotope 13C which occurs naturally in carbon at about the 1.1% level. 14C has been used extensively to trace the progress of organic molecules through metabolic pathways.
Many of the medications used in feminizing hormone therapy, such as estradiol, cyproterone acetate, and bicalutamide, are substrates of CYP3A4 and other cytochrome P450 enzymes. As a result, inducers of CYP3A4 and other cytochrome P450 enzymes, such as carbamazepine, phenobarbital, phenytoin, rifampin, rifampicin, and St. John's wort, among others, may decrease circulating levels of these medications and thereby decrease their effects. Conversely, inhibitors of CYP3A4 and other cytochrome P450 enzymes, such as cimetidine, clotrimazole, grapefruit juice, itraconazole, ketoconazole, and ritonavir, among others, may increase circulating levels of these medications and thereby increase their effects. The concomitant use of a cytochrome P450 inducer or inhibitor with feminizing hormone therapy may necessitate medication dosage adjustments.
This practice later expanded to white wigs and eyeliners, and only faded out with the French Revolution in the late 18th century. A similar fashion appeared in Japan in the 18th century with the emergence of the geishas, a practice that continued long into the 20th century. The white faces of women "came to represent their feminine virtue as Japanese women", with lead commonly used in the whitener.
== Diagnosis == Echocardiography is the preferred screening test in the diagnosis of PAH as it accurately estimates pulmonary pressures. Other causes of pulmonary hypertension, such as left heart disease (WHO group 2), pulmonary hypertension due to lung disease (such as COPD)(WHO group 3) and pulmonary hypertension due to chronic blood clots in the pulmonary arteries (WHO group 4) need to be ruled out. Some tests which are commonly used include a CT scan of the chest, ventilation perfusion scan or a CT angiography (to rule out pulmonary hypertension due to chronic blood clots), pulmonary function test, and a cardiac MRI. Cardiac MRI is the preferred test to evaluate right ventricular structure and function in PAH. Pulmonary function testing in PAH may show an obstructive or restrictive defect, and the diffusion capacity of carbon monoxide (used as a surrogate for gas exchange in the alveoli) is reduced. A sleep study helps to rule out sleep disordered breathing, such as sleep apnea, which may contribute to PAH. The N-terminal prohormone of brain natriuretic peptide (NT pro-BNP) may be monitored in those with PAH and is prognostic. A right heart catheterization to measure right heart pressure is required for the diagnosis of PAH.
Sources: en.wikipedia.org
=== Formulations and compositions === Docetaxel is a white powder and is the active ingredient available in 20 mg and 80 mg Taxotere single-dose vials of concentrated anhydrous docetaxel in polysorbate 80. The solution is a clear brown-yellow containing 40 mg docetaxel and 1040 mg polysorbate 80 per mL. 20 mg Taxotere is distributed in a blister carton containing one single-dose vial of Taxotere (docetaxel) preparation in 0.5 mL sterile pyrogen-free anhydrous polysorbate 80, and a single dose Taxotere solvent vial containing 1.5 mL 13% ethanol in saline to be combined and diluted in a 250 mL infusion bag containing 0.9% sodium chloride or 5% glucose for administration. 80 mg Taxotere is supplied identically but with 2.0 mL polysorbate 80 and 6.0 mL 13% ethanol in saline. The docetaxel and solvent vials are combined to give a solution of 10 mg/mL and the required dose is drawn from this solution. Vials have an overfill to compensate for liquid loss during preparation, foaming, adhesion to vial walls and the dead volume. 20 mg vials may be stored for 24 months below 25 °C away from light and 80 mg vials for 26 months in the same conditions. Recently Sanofi has got approval for one-vial formulation. With this one-vial formulation, the preparation of the infusion solution is simplified by eliminating the first dilution step. The two-vial and one-vial formulations contain the same drug substance, docetaxel trihydrate, and the same excipients (ethanol, polysorbate 80 and citric acid).
== Businesspeople == Henry Rutgers (1766), Revolutionary War hero, businessman, philanthropist, and namesake of Rutgers University Leffert Lefferts (1794), first president of Long Island Bank William Bard (1798), son of physician Samuel Bard, founder and first president of New York Life Insurance Company Stephen Price (1799), theatrical manager who managed Park Theatre in Manhattan and Theatre Royal, Drury Lane in London William Backhouse Astor Sr.* (1811), son of John Jacob Astor Cornelius Roosevelt* (attended, year unknown), member of the Roosevelt family, one of the founders of the Chemical Bank; great-grandfather of Theodore Roosevelt James H. Roosevelt (1819), founder of Roosevelt Hospital Robert Goelet Sr. (1828), banker and real estate developer who was associated with the founding of the Chemical Bank Bradish Johnson (1831), industrialist involved in the Swill milk scandal Robert L. Cutting (1830), co-founder of the Continental Bank of New York and president of the New York Stock Exchange Henry T. Anthony (1832), photographer, vice-president of the E. & H. T. Anthony & Company Adrian G Iselin* (1837), financier, banker Edward Anthony (1838), photographer and founder of E. & H. T. Anthony & Company, largest manufacturer and distributor of photographic supplies in the U.S. during the 19th century John Jacob Astor III (1839), son of William Backhouse Astor Sr.
In June 1998, Caldwell Dyson was selected by NASA, and began NASA training two months later, in August 1998. Her astronaut candidate training included orientation briefings and tours, numerous scientific and technical briefings, intensive instruction in Shuttle and International Space Station (ISS) systems, physiological training, ground school to prepare for T-38 flight training, as well as learning water and wilderness survival techniques. Completion of this training and evaluation qualified her for flight assignment as a mission specialist. In 1999, Caldwell Dyson was assigned to the Astronaut Office ISS Operations Branch as a Russian Crusader, participating in the testing and integration of Russian hardware and software products developed for ISS. In 2000, she was assigned prime crew support astronaut for the ISS Expedition 5 crew, serving as their representative on technical and operational issues throughout the training and on-orbit phase of their mission. During ISS Expeditions 4 through 6, Caldwell Dyson served as an ISS spacecraft communicator (CAPCOM) inside Mission Control. In 2003, she made a transition to the Astronaut Shuttle Operations Branch and was assigned to flight software verification in the Shuttle Avionics Integration Laboratory and worked supporting launch and landing operations at Kennedy Space Center, Florida. Caldwell Dyson also served as Lead CAPCOM for Expedition 11.
Potatoes Sweet potatoes Tomatoes Onions and Cabbage In 2013 global fruit production was estimated at 676.9 million tonnes (666,200,000 long tons; 746,200,000 short tons). Global vegetable production (including melons) was estimated at 879.2 million tonnes (865,300,000 long tons; 969,200,000 short tons) with China and India being the two top producing countries.
Microfibrillated cellulose (MFC) was discovered later, in the 1980s, by Turbak, Snyder and Sandberg at the ITT Rayonier labs in Shelton, Washington. This terminology was used to describe a gel-like material prepared by passing wood pulp through a Gaulin type milk homogenizer at high temperatures and high pressures followed by ejection impact against a hard surface. In later work, F. W. Herrick at ITT Rayonier Eastern Research Division (ERD) Lab in Whippany also published work on making a dry powder form of the gel. Rayonier, as a company, never pursued scale-up and gave free license to whoever wanted to pursue this new use for cellulose. Rather, Turbak et al. pursued 1) finding new uses for the MFC, including using as a thickener and binder in foods, cosmetics, paper formation, textiles, nonwovens, etc. and 2) evaluate swelling and other techniques for lowering the energy requirements for MFC production. The first MFC pilot production plant of MFC was established in 2010 by Innventia AB (Sweden).
Sources: en.wikipedia.org
In geometry, triangle inequalities are inequalities involving the parameters of triangles, that hold for every triangle, or for every triangle meeting certain conditions. The inequalities give an ordering of two different values: they are of the form "less than", "less than or equal to", "greater than", or "greater than or equal to". The parameters in a triangle inequality can be the side lengths, the semiperimeter, the angle measures, the values of trigonometric functions of those angles, the area of the triangle, the medians of the sides, the altitudes, the lengths of the internal angle bisectors from each angle to the opposite side, the perpendicular bisectors of the sides, the distance from an arbitrary point to another point, the inradius, the exradii, the circumradius, and/or other quantities. Unless otherwise specified, this article deals with triangles in the Euclidean plane.
The umbilical is the standard option for delivery for commercial diving operations. It contains a hose to supply the breathing gas and usually several other components, which may be stipulated by legislation or code of practice. These usually include a communications cable (comms wire), a pneumofathometer, and a strength member, which may be the airline hose, the communications cable, or a rope. When needed, a hot water supply line, helium reclaim line, video camera and lighting cables may be included. These components are bundled and taped, or neatly twisted into a multistrand cable, and are deployed as a single unit. The diver's end has underwater connectors for the electrical cables, and the air hoses are usually connected to the helmet, band mask, or bailout block by JIC fittings. A screw-gate carabiner or similar connector is provided on the strength member for attachment to the diver's harness, and may be used to lift the diver in an emergency. Similar connections are provided for attachment to the diving bell, if used, or to the surface gas panel and communications equipment. A diver's umbilical supplied from a bell gas panel is called an excursion umbilical, and the supply from the surface to the bell panel is the bell umbilical.
== Applications == A major application of FD is to determine the molecular mass of a large variety of thermally labile and stable nonvolatile, nonpolar, and polar organic and organometallic compounds, and of molecules from biochemical and environmental sources.
The developer of the Half-Life series, Valve, was founded in 1996 in Kirkland, Washington by the former Microsoft employees Mike Harrington and Gabe Newell. Valve began working on the first Half-Life soon after formation, and settled on a concept for a horror-themed 3D action game, using the Quake engine as licensed by id Software. The game was a hit at the 1997 E3 convention, where its animation system and artificial intelligence were demonstrated. The success led to its first expansion pack, Half-Life: Opposing Force, which was developed by Gearbox Software, a new company based in Plano, Texas, and announced on April 15, 1999. The Gearbox founder, Randy Pitchford, said Valve gave them the project to allow Valve to focus on future games. Opposing Force was demonstrated at the 1999 E3 convention, where new locations, characters and the story were revealed. The second Half-Life expansion pack, Half-Life: Blue Shift, was again developed by Gearbox Software and announced by its publisher, Sierra Entertainment, on August 30, 2000. Sierra intended to release Blue Shift for the Dreamcast, and it was set to include higher detail models and textures that were double the polygon count of the models from Half-Life. However, after several months of delays, Sierra terminated the Dreamcast version of Blue Shift on June 16, 2001, and instead released it for Windows on June 12. Afterward, Gearbox began working on a Half-Life game for the PlayStation 2.
== Ligands == The AMYRs are bound by amylin with high affinity, and by calcitonin with relatively lower affinity. In humans, calcitonin gene-related peptide (CGRP) is a selective agonist with a greater affinity towards AMY1 than AMY3, while its affinity for AMY2 isn’t well understood. Drugs that mimic Amylin to activate amylin receptors (called Amylin receptor agonists) are being developed as therapies for diabetes and obesity, and one, pramlintide, has been FDA approved as a treatment for diabetes. CGRP receptor antagonists which are being developed for migraine, may also act as antagonists for AMY1, which could be playing a role in their effects. Dual agonists of the amylin and calcitonin receptors (DACRAs) are under development for obesity. Amylin and its receptors are believed to play a role in Alzheimer's disease.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.